Literature DB >> 18947327

Kidney disease in patients with HIV infection and AIDS.

Jonathan Winston1, Gilbert Deray, Trevor Hawkins, Lynda Szczech, Christina Wyatt, Benjamin Young.   

Abstract

As patients infected with human immunodeficiency virus (HIV) live longer while receiving antiretroviral therapy, kidney diseases have emerged as significant causes of morbidity and mortality. Black race, older age, hypertension, diabetes, low CD4(+) cell count, and high viral load remain important risk factors for kidney disease in this population. Chronic kidney disease should be diagnosed in its early stages through routine screening and careful attention to changes in glomerular filtration rate or creatinine clearance. Hypertension and diabetes must be aggressively treated. Antiretroviral regimens themselves have been implicated in acute or chronic kidney disease. The risk of kidney disease associated with the widely used agent tenofovir continues to be studied, although its incidence in reported clinical trials and observational studies remains quite low. Future studies about the relationship between black race and kidney disease, as well as strategies for early detection and intervention of kidney disease, hold promise for meaningful reductions in morbidity and mortality associated with kidney disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18947327     DOI: 10.1086/593099

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  29 in total

Review 1.  An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature.

Authors:  Christine B Bruno; Jeffrey M Schapiro; Parya Saberi
Journal:  J Int Assoc Physicians AIDS Care (Chic)       Date:  2011-04-25

2.  Cardiovascular risks associated with abacavir and tenofovir exposure in HIV-infected persons.

Authors:  Andy I Choi; Eric Vittinghoff; Steven G Deeks; Cristin C Weekley; Yongmei Li; Michael G Shlipak
Journal:  AIDS       Date:  2011-06-19       Impact factor: 4.177

3.  Renal insufficiency in Ghanaian HIV infected patients: need for dose adjustment.

Authors:  W K B A Owiredu; L Quaye; N Amidu; O Addai-Mensah
Journal:  Afr Health Sci       Date:  2013-03       Impact factor: 0.927

4.  HIV-positive-to-HIV-positive kidney transplantation.

Authors:  Elmi Muller; Zunaid Barday; Delawir Kahn
Journal:  N Engl J Med       Date:  2015-05-21       Impact factor: 91.245

5.  Renal events among women treated with tenofovir/emtricitabine in combination with either lopinavir/ritonavir or nevirapine.

Authors:  Albert Mwafongo; Kondwani Nkanaunena; Yu Zheng; Evelyn Hogg; Wadzanai Samaneka; Lloyd Mulenga; Abraham Siika; Judith Currier; Shahin Lockman; Michael D Hughes; Mina Hosseinipour
Journal:  AIDS       Date:  2014-05-15       Impact factor: 4.177

6.  Classification of human immunodeficiency virus-infected patients with chronic kidney disease using a combination of proteinuria and estimated glomerular filtration rate.

Authors:  Naoki Yanagisawa; Takashi Muramatsu; Yasuyuki Yamamoto; Ken Tsuchiya; Kosaku Nitta; Atsushi Ajisawa; Katsuyuki Fukutake; Minoru Ando
Journal:  Clin Exp Nephrol       Date:  2013-08-17       Impact factor: 2.801

7.  Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175).

Authors:  F Touzard Romo; L M Smeaton; T B Campbell; C Riviere; R Mngqibisa; M Nyirenda; K Supparatpinyo; N Kumarasamy; J G Hakim; T P Flanigan
Journal:  HIV Clin Trials       Date:  2014 Nov-Dec

Review 8.  The treatment of HIV-associated nephropathy.

Authors:  Robert C Kalayjian
Journal:  Adv Chronic Kidney Dis       Date:  2010-01       Impact factor: 3.620

9.  HIV and the Kidney.

Authors:  Leslie A Bruggeman; Charles Bark; Robert C Kalayjian
Journal:  Curr Infect Dis Rep       Date:  2009-11       Impact factor: 3.725

Review 10.  The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists.

Authors:  Giuseppe Coppolino; Mariadelina Simeoni; Chiara Summaria; Maria Concetta Postorino; Laura Rivoli; Alessio Strazzulla; Carlo Torti; Giorgio Fuiano
Journal:  J Nephrol       Date:  2015-06-09       Impact factor: 3.902

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.